Labcorp Holdings Inc. (LH)
Market Cap | 19.12B |
Revenue (ttm) | 12.71B |
Net Income (ttm) | 435.50M |
Shares Out | 83.64M |
EPS (ttm) | 5.14 |
PE Ratio | 44.52 |
Forward PE | 14.91 |
Dividend | $2.88 (1.26%) |
Ex-Dividend Date | Nov 26, 2024 |
Volume | 460,432 |
Open | 227.85 |
Previous Close | 226.97 |
Day's Range | 226.56 - 229.74 |
52-Week Range | 191.97 - 247.99 |
Beta | 1.04 |
Analysts | Buy |
Price Target | 258.29 (+12.98%) |
Earnings Date | Feb 13, 2025 |
About LH
Labcorp Holdings Inc. provides laboratory services. It operates through two segments, Diagnostics Laboratories and Biopharma Laboratory Services. The company offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid, PAP, hemoglobin A1C and vitamin D, prostate-specific antigens, sexually transmitted diseases, hepatitis C, microbiology cultures and procedures, and alcohol and other substance-abuse tests. It also provides specialty testing services comprising gene-based and esoteric testing; advanced tests tar... [Read more]
Financial Performance
In 2023, Labcorp Holdings's revenue was $12.16 billion, an increase of 2.51% compared to the previous year's $11.86 billion. Earnings were $418.00 million, a decrease of -67.32%.
Financial StatementsAnalyst Forecast
According to 16 analysts, the average rating for LH stock is "Buy." The 12-month stock price forecast is $258.29, which is an increase of 12.98% from the latest price.
News
Labcorp Launches H5 Bird Flu Test in the U.S., Now Available for Order through Physicians
New test supports public health preparedness efforts and testing infrastructure amid multistate outbreak of H5 bird flu in poultry and dairy cows BURLINGTON, N.C. , Dec. 17, 2024 /PRNewswire/ -- Labco...
Be Patient, Earn Dividends From Labcorp, The Leading Patient Clinical Lab Brand
For my initial coverage of Labcorp, I'm calling it a hold, and an opportunity to earn a $0.72/share quarterly dividend on the leading clinical lab company in the US. The firm shows future growth indic...
Outcomes4Me and Labcorp Study Reveals Digital Education Can Increase HER2-low Awareness for Metastatic Breast Cancer Patients
Research to be presented in a joint poster session with Labcorp at the 2024 San Antonio Breast Cancer Symposium BOSTON and BURLINGTON, N.C. , Nov. 26, 2024 /PRNewswire/ -- Outcomes4Me Inc., the develo...
Cinven secures Italian nod to sell minority stake in Synlab to Labcorp
Private equity firm Cinven secured a conditional approval from Italian authorities over its plan to sell a 15% stake in diagnostic service provider Synlab to laboratory operator Labcorp , a government...
Labcorp CFO Glenn Eisenberg Announces Plans to Retire
Julia Wang Named Chief Financial Officer Beginning December 2, 2024 BURLINGTON, N.C. , Nov. 19, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory serv...
Praia Health Secures Strategic Investment from Labcorp Venture Fund, Announces New Collaboration to Streamline Patient Lab Ordering Experience
CHICAGO & BURLINGTON, N.C.--(BUSINESS WIRE)--Collaboration leverages Praia Health's technology and Labcorp's comprehensive testing capabilities to streamline and personalize patient experience.
Labcorp Holdings Inc. (LH) Q3 2024 Earnings Call Transcript
Labcorp Holdings Inc. (NYSE:LH) Q3 2024 Earnings Conference Call October 24, 2024 9:00 AM ET Company Participants Christin O'Donnell – Vice President-Investor Relations Adam Schechter – Chairman and ...
Laboratory Corp Q3 Earnings Beat Street View, Investors Overlook Hurricane Helene Impact
Thursday, Laboratory Corp LH reported third-quarter 2024 adjusted earnings per share of $3.50, up from $3.38 a year ago, beating the consensus of $3.49.
Labcorp beats quarterly estimates on diagnostic test demand
Laboratory operator Labcorp on Thursday beat Wall Street estimates for third-quarter profit and revenue, helped by demand for diagnostic tests.
Labcorp Announces 2024 Third Quarter Results
Updates Full-Year Guidance Results from Continuing Operations for third quarter 2024 versus last year: Revenue: $3.28 billion versus $3.06 billion Diluted EPS: $2.00 versus $2.11 Adjusted EPS: $3.50 v...
NOWDiagnostics and Labcorp Collaborate to Expand Access to the Only FDA-Marketing Authorized Over-the-Counter Syphilis Test in the U.S.
SPRINGDALE, Ark.--(BUSINESS WIRE)--NOWDiagnostics, Inc. (NOWDx), a developer of over-the-counter (OTC) and point-of-care (POC) diagnostic tests, today announced that Labcorp, a global leader of innova...
Labcorp Expands Sexually Transmitted Infection (STI) Test Offerings with Rapid Syphilis Test
Labcorp to serve as the exclusive NOWDiagnostics (NOWDx) distributor for clinical testing in the U.S., offering First to Know® Syphilis Test nationwide BURLINGTON, N.C. , Oct 10, 2024 /PRNewswire/ -- ...
Labcorp Declares Quarterly Dividend
BURLINGTON, N.C. , Oct. 10, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today that its Board of Directors has declared a cas...
Labcorp to Announce Third Quarter Financial Results on October 24, 2024
BURLINGTON, N.C. , Sept. 24, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, will release its financial results for the third quarter of 2...
CommonWell Health Alliance Welcomes Labcorp as Newest Member
BOSTON--(BUSINESS WIRE)--CommonWell Health Alliance is excited to welcome Labcorp, a global leader of innovative and comprehensive laboratory services, as one of its newest members in the ongoing jour...
Ovia Health Expands Women's Health Offerings with Comprehensive Postpartum Experience
New solution is the first holistic program available in a digital app to help women manage the postpartum period BOSTON , Sept. 18, 2024 /PRNewswire/ -- Ovia Health by Labcorp (Ovia) today announced t...
LABCORP PRICES $650,000,000 IN 4.350% SENIOR NOTES DUE 2030, $500,000,000 IN 4.550% SENIOR NOTES DUE 2032 AND $850,000,000 IN 4.800% SENIOR NOTES DUE 2034
BURLINGTON, N.C. , Sept. 16, 2024 /PRNewswire/ -- Labcorp Holdings Inc. (NYSE:LH) (Labcorp) announced today that its wholly owned subsidiary, Laboratory Corporation of America Holdings (LCAH), has pri...
Labcorp Completes Acquisition of Select Assets of BioReference Health's Diagnostics Business from OPKO Health
Enhances Labcorp's laboratory services network and expands access to its clinical services BURLINGTON, N.C. and MIAMI , Sept.
Xcell Biosciences Advances Labcorp Collaboration with Novel Platform for Automated Cell and Gene Therapy Manufacturing
SAN FRANCISCO--(BUSINESS WIRE)--Xcell Biosciences Inc. (Xcellbio), an instrumentation company focused on cell and gene therapy applications, today announced it has advanced its collaboration with Labc...
Labcorp to Speak at the Baird 2024 Global Healthcare Conference
BURLINGTON, N.C. , Sept. 3, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today that members of the executive management team ...
Labcorp says it could ramp up mpox testing capacity
Diagnostics firm Labcorp said it is processing approximately 500 mpox tests a month but have the capacity to process approximately 25,000 per month.
Labcorp Finalizes Acquisition of Select Assets of Invitae
Extends Labcorp's leadership in genetic testing solutions for oncology and select rare diseases BURLINGTON, N.C. , Aug. 5, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and co...
5 Stocks That Have Bucked August's Selloff, and How They've Done It
August has already made it a cruel summer for stocks.
LabCorp Analysts Boost Their Forecasts After Better-Than-Expected Earnings
Labcorp Holdings Inc LH reported better-than-expected second-quarter financial results and raised its FY24 revenue guidance above estimates on Thursday.
Labcorp Receives FDA De Novo Marketing Authorization for PGDx elio™ plasma focus Dx
PGDx elio™ plasma focus Dx is the industry's first and only kitted, pan-solid tumor liquid biopsy test that enables tumor mutation profiling – all from a simple blood draw BURLINGTON, N.C., Aug. 2, 20...